Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sorrento Therapeutics, Inc.
Study CGT-LTFU-35 is an observational study of patients who have been exposed to a gene-modified cell therapy (GMCT) produced by ex vivo transduction of immune cells expressing viral and/or non-viral vectors in studies sponsored by Sorrento Therapeutics, Inc. Patients are to be followed for up to 15 years after exposure to a GMCT agent for the possible development of long-term adverse events and efficacy outcomes.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have received any amount of a CGT in a study sponsored by Sorrento Therapeutics, Inc.
You may not be if
Unable or unwilling to provide written informed consent and/or comply with study requirements.
Clareo Health | Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy
